Ubs Group Ag Dice Therapeutics, Inc. Transaction History

Ubs Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$25.86 - $46.71 $9.91 Million - $17.9 Million	383,140 Added 2373.27%	399,284 $18.6 Million
Q1 2023 May 12, 2023	BUY	$26.05 - $32.31 $183,860 - $228,043	7,058 Added 77.68%	16,144 $462,000
Q4 2022 Feb 08, 2023	BUY	$19.77 - $42.23 $177,198 - $378,507	8,963 Added 7286.99%	9,086 $283,000
Q3 2022 Nov 10, 2022	BUY	$14.97 - $22.65 $1,841 - $2,785	123 New	123 $2,000
Q2 2022 Aug 10, 2022	SELL	$13.19 - $22.1 $27,158 - $45,503	-2,059 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$14.54 - $25.02 $34,488 - $59,347	-2,372 Reduced 53.53%	2,059 $39,000
Q4 2021 Feb 14, 2022	BUY	$22.41 - $37.54 $99,298 - $166,339	4,431 New	4,431 $112,000

17.7K

13K

Ticker DICE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,430,000
Description
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lea...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.